Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

    • holestatic pruritus

    - PMLiVE

    Novo Nordisk reports phase 3 data showing semaglutide reduces liver scarring

    Patients with MASH in the ESSENCE phase 3 trial show semaglutide’s potential to improve liver health

    - PMLiVE

    GSK’s Blenrep approved by FDA for multiple myeloma

    Approval supported by positive results from phase 3 trial

    - PMLiVE

    Roche to acquire 89bio in a deal worth up to US$3.5bn

    With the agreement, Roche will gain a treatment for moderate to severe MASH

    - PMLiVE

    GSK and Hengrui enter multi-programme collaboration agreement worth $12bn

    The deal includes a PDE3/4 inhibitor in clinical development for COPD

    - PMLiVE

    GSK’s Blenrep combinations granted EC approval for relapsed/refractory multiple myeloma

    More than 50,000 cases of the blood cancer are diagnosed in Europe each year

    - PMLiVE

    GSK’s Blenrep combination recommended by NICE to treat multiple myeloma

    The decision means that eligible patients in England will be the first in the world to access the combination

    - PMLiVE

    GSK to acquire Boston’s liver disease candidate efimosfermin in deal worth up to $2bn

    Steatotic liver disease affects approximately 5% of the global population

    - PMLiVE

    Madrigal’s liver disease drug Rezdiffra shows promise in compensated MASH cirrhosis

    The drug has already been approved in the US to treat patients with non-cirrhotic MASH

    - PMLiVE

    GSK shares promising phase 3 results for linerixibat in PBC-related itch

    Pruritus is experienced by up to 90% of patients with the rare liver disease

    - PMLiVE

    Ipsen’s elafibranor shows promise in rare liver disease primary sclerosing cholangitis

    The drug already holds approvals to treat primary biliary cholangitis, another rare liver disease

    - PMLiVE

    GSK’s Blenrep combinations approved by MHRA to treat multiple myeloma

    Approximately 6,500 new cases of the blood cancer are diagnosed in the UK each year

    - PMLiVE

    GSK’s five-in-one meningococcal vaccine recommended by CDC advisory committee

    Penmenvy combines the antigenic components of GSK's approved Bexsero and Menveo vaccines

    Subscribe to our email news alerts

    Latest content

    Latest intelligence

    Quick links